Kiora Pharmaceuticals, Inc. (KPRX)
| Market Cap | 11.12M +19.6% |
| Revenue (ttm) | n/a |
| Net Income | -11.06M |
| EPS | -2.66 |
| Shares Out | 4.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,232 |
| Open | 2.530 |
| Previous Close | 2.550 |
| Day's Range | 2.500 - 2.560 |
| 52-Week Range | 1.765 - 3.290 |
| Beta | -0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre... [Read more]
Financial Performance
Financial StatementsNews
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual O...
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase...
Kiora Pharmaceuticals Slides: Corporate presentation
Kiora Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Kiora Pharmaceuticals files to sell 11.8M shares of common stock for holders
16:33 EDT Kiora Pharmaceuticals (KPRX) files to sell 11.8M shares of common stock for holders
Kiora Pharmaceuticals Registration statement: Registration filing
Kiora Pharmaceuticals filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its ...
Kiora Pharmaceuticals Quarterly report: Q1 2026
Kiora Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
Kiora Pharmaceuticals Earnings release: Q1 2026
Kiora Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Kiora Pharmaceuticals Proxy statement: Proxy filing
Kiora Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medi...
Kiora Pharmaceuticals Announces Management Team Changes
Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D.
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ...
Kiora Pharmaceuticals Earnings release: Q4 2025
Kiora Pharmaceuticals released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Kiora Pharmaceuticals Annual report: Q4 2025
Kiora Pharmaceuticals has published its Q4 2025 annual report on March 25, 2026.
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sc...
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal dis...
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on...
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an ...
Kiora Pharmaceuticals Earnings release: Q3 2025
Kiora Pharmaceuticals released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Kiora Pharmaceuticals Quarterly report: Q3 2025
Kiora Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 7, 2025.
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
ENCINITAS, Calif. and WASHINGTON D.C.
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Gr...
Kiora Pharmaceuticals files $100M mixed securities shelf
16:18 EDT Kiora Pharmaceuticals (KPRX) files $100M mixed securities shelf
Kiora Pharmaceuticals Registration statement: Registration Filing
Kiora Pharmaceuticals filed a registration statement on September 15, 2025, providing details about a securities offering with the SEC.
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an u...